{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.71","value":"85.2"},{"groupId":"OG001","spread":"8.50","value":"88.4"},{"groupId":"OG002","spread":"7.97","value":"102.0"}]}],"title":"Screening, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.32","value":"84.3"},{"groupId":"OG001","spread":"12.89","value":"88.2"},{"groupId":"OG002","spread":"13.22","value":"102.4"}]}],"title":"Day 1, n=4, 5, 5,"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79","value":"85.3"},{"groupId":"OG001","spread":"11.19","value":"90.8"},{"groupId":"OG002","spread":"8.47","value":"103.8"}]}],"title":"Week 1, n= 4, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.97","value":"80.4"},{"groupId":"OG001","spread":"16.77","value":"84.4"},{"groupId":"OG002","spread":"10.66","value":"96.8"}]}],"title":"Week 2, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.16","value":"92.8"},{"groupId":"OG001","spread":"11.04","value":"91.4"},{"groupId":"OG002","spread":"11.10","value":"106.2"}]}],"title":"Week 3, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.92","value":"86.4"},{"groupId":"OG001","spread":"7.62","value":"84.0"},{"groupId":"OG002","spread":"14.29","value":"98.6"}]}],"title":"Week 4, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.48","value":"84.6"},{"groupId":"OG001","spread":"9.58","value":"88.4"},{"groupId":"OG002","spread":"9.58","value":"107.8"}]}],"title":"Week 5, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.50","value":"76.4"},{"groupId":"OG001","spread":"13.79","value":"89.8"},{"groupId":"OG002","spread":"8.29","value":"103.0"}]}],"title":"Week 6, n=5, 5, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.46","value":"82.0"},{"groupId":"OG001","spread":"17.84","value":"96.2"},{"groupId":"OG002","spread":"8.93","value":"103.2"}]}],"title":"Week 7, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.20","value":"83.0"},{"groupId":"OG001","spread":"15.04","value":"89.4"},{"groupId":"OG002","spread":"10.62","value":"111.8"}]}],"title":"Week 8, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.35","value":"80.4"},{"groupId":"OG001","spread":"11.34","value":"79.2"},{"groupId":"OG002","spread":"5.59","value":"101.6"}]}],"title":"Week 9, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.93","value":"80.6"},{"groupId":"OG001","spread":"10.31","value":"84.4"},{"groupId":"OG002","spread":"9.29","value":"105.4"}]}],"title":"Week 10, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.04","value":"86.6"},{"groupId":"OG001","spread":"16.50","value":"97.7"},{"groupId":"OG002","spread":"11.19","value":"106.6"}]}],"title":"Week 11, n=5, 3, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.07","value":"80.5"},{"groupId":"OG001","spread":"12.83","value":"92.0"},{"groupId":"OG002","spread":"16.62","value":"101.4"}]}],"title":"Week 12, n=4, 4, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.52","value":"90.8"},{"groupId":"OG001","spread":"7.05","value":"86.5"},{"groupId":"OG002","spread":"3.50","value":"103.8"}]}],"title":"Week 13, n=4, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.85","value":"81.0"},{"groupId":"OG001","spread":"8.66","value":"87.0"},{"groupId":"OG002","spread":"11.00","value":"101.0"}]}],"title":"Week 14, n=3, 3, 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.66","value":"77.3"},{"groupId":"OG001","spread":"11.87","value":"86.8"},{"groupId":"OG002","spread":"3.87","value":"102.5"}]}],"title":"Week 15, n=3, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.60","value":"86.4"},{"groupId":"OG001","spread":"5.57","value":"103.0"},{"groupId":"OG002","spread":"18.96","value":"93.0"}]}],"title":"Week 16, n=5, 3, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.51","value":"67.5"},{"comment":"There were no participants analyzed at this time point, therefore there is no calculated standard deviation.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"12.01","value":"97.7"}]}],"title":"Week 17, n=2, 0, 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.44","value":"88.0"},{"groupId":"OG001","spread":"17.01","value":"86.7"},{"groupId":"OG002","spread":"16.88","value":"102.8"}]}],"title":"Week 18, n=3, 3, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.81","value":"88.0"},{"comment":"There were no participants analyzed at this time point, therefore there is no calculated standard deviation.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"8.49","value":"94.0"}]}],"title":"Week 19, n=3, 0, 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.03","value":"79.8"},{"groupId":"OG001","spread":"12.58","value":"96.8"},{"groupId":"OG002","spread":"14.97","value":"111.8"}]}],"title":"Week 20, n=5, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.93","value":"79.0"},{"groupId":"OG001","spread":"3.54","value":"75.5"},{"groupId":"OG002","spread":"18.63","value":"101.0"}]}],"title":"Week 21, n=3, 2, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.36","value":"70.3"},{"groupId":"OG001","spread":"9.04","value":"86.5"},{"groupId":"OG002","spread":"18.63","value":"100.0"}]}],"title":"Week 22, n=3, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.03","value":"71.5"},{"groupId":"OG001","spread":"3.54","value":"82.5"},{"groupId":"OG002","spread":"13.14","value":"100.0"}]}],"title":"Week 23, n=4, 2, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.86","value":"79.6"},{"groupId":"OG001","spread":"6.91","value":"85.8"},{"groupId":"OG002","spread":"4.74","value":"96.0"}]}],"title":"Week 24, n=5, 5, 5"},{"categories":[{"measurements":[{"comment":"There were too few participants available to collect data at this time point to calculate a standard deviation.","groupId":"OG000","spread":"NA","value":"81.0"},{"comment":"There were too few participants available to collect data at this time point to calculate a standard deviation.","groupId":"OG001","spread":"NA","value":"125.0"},{"groupId":"OG002","spread":"10.79","value":"107.7"}]}],"title":"FU Week 1, n=1, 1, 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.74","value":"77.7"},{"groupId":"OG001","spread":"28.99","value":"84.5"},{"comment":"There were no participants analyzed at this time point, therefore there is no calculated standard deviation.","groupId":"OG002","spread":"NA","value":"NA"}]}],"title":"FU Week 2, n=3, 2, 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.83","value":"87.0"},{"comment":"There were too few participants available to collect data at this time point to calculate a standard deviation.","groupId":"OG001","spread":"NA","value":"78.0"},{"groupId":"OG002","spread":"8.49","value":"98.0"}]}],"title":"FU Week 3, n=2, 1, 2"},{"categories":[{"measurements":[{"comment":"There were too few participants available to collect data at this time point to calculate a standard deviation.","groupId":"OG000","spread":"NA","value":"89.0"},{"comment":"There were no participants analyzed at this time point, therefore there is no calculated standard deviation.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"26.87","value":"99.0"}]}],"title":"FU Week 4, n=1, 0, 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.01","value":"108.8"},{"groupId":"OG001","spread":"14.17","value":"109.8"},{"groupId":"OG002","spread":"5.73","value":"119.6"}]}],"title":"MBP, n=5, 5, 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline (MPB) visit included any scheduled and unscheduled post-Baseline assessment..","dispersionType":"Standard Deviation","groups":[{"description":"Participants aged between 12 and 17 years received a 24-week Open-label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was 25 milligrams (mg), once daily (QD). The participants of East Asian ancestry began at 12.5mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG000","title":"Part 1 (Dose-Finding Period) Cohort 1"},{"description":"Participants aged between 6 and 11 years received a 24-week Open-Label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was based on the body weight. Participants with a weight of \\<27 kilograms (kg) received 12.5 mg QD (approximately 0.5 - 0.7 mg/kg QD) and participants with a weight of \\>=27 kg received 25 mg QD (approximately 0.5 - 0.8 mg/kg QD). The maximum dose allowed was 2 mg/kg and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG001","title":"Part 1 (Dose-Finding Period) Cohort 2"},{"description":"Participants aged between 1 and 5 years received a 24-week Open-Label treatment of eltrombopag administered as a dry powder for oral suspension. The starting dose of eltrombopag was 0.7 mg/kg QD. Participants of East Asian ancestry began at 0.5 mg/kg/day. The maximum dose allowed was 2 mg/kg, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG002","title":"Part 1 (Dose-Finding Period) Cohort 3"}],"paramType":"MEAN","populationDescription":"Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Safety Population","reportingStatus":"POSTED","timeFrame":"From Week 1 to Follow-up Week 4 of Part 1, up to Study Week 28","title":"Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1","type":"SECONDARY","unitOfMeasure":"Beats per minute"}